David Perkins
Internal Medicine · St Davids, PANPI 1558399857
Payments from drug & device makers
Across 59 payments — averaging $91.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$523
- Insmed, Inc.$271
- Optinose US, Inc.$251
- Novo Nordisk$250
- Janssen Scientific Affairs, LLC$238
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$2,12539%
- Food & beverage$3,27061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $2,480 |
| AstraZeneca(2 entities) | 7 | $523 |
| Insmed, Inc. | 2 | $271 |
| Optinose US, Inc. | 3 | $251 |
| Novo Nordisk | 6 | $250 |
| Janssen Scientific Affairs, LLC | 2 | $238 |
| Bayer | 4 | $230 |
| Merck | 2 | $134 |
| Amarin Pharma, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $120 |
| Sanofi | 1 | $116 |
| Amgen | 2 | $104 |
| Shire North American Group Inc | 1 | $102 |
| Boehringer Ingelheim | 1 | $102 |
| Lilly USA, LLC | 4 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Exact Sciences | 2 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Eisai Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Abbott | 1 | $21 |
| GSK | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Shield Therapeutics Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,395 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $45,319 |
| EntrestoSacubitril/Valsartan | 37 | $24,239 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $21,839 |
| JardianceEmpagliflozin | 35 | $20,650 |
| LinzessLinaclotide | 38 | $19,859 |
| SynthroidLevothyroxine Sodium | 16 | $1,839 |
| Ezetimibe | 50 | $1,824 |
| Midodrine Hcl | 11 | $1,274 |
| Atorvastatin Calcium | 100 | $1,071 |
| Rosuvastatin Calcium | 91 | $965 |
| Celecoxib | 15 | $862 |
| Levothyroxine Sodium | 68 | $714 |
| Amlodipine Besylate | 55 | $678 |
| Escitalopram Oxalate | 25 | $610 |
| Metoprolol Succinate | 35 | $609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $45,31962 claims |
| GSKTrelegy Ellipta | $19 | $21,83935 claims |
| AbbVieLinzess, Synthroid | $2,480 | $21,69754 claims |
| Boehringer IngelheimJardiance | $102 | $20,65035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in St Davids
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.